• Je něco špatně v tomto záznamu ?

Effect of Oxime Encapsulation on Acetylcholinesterase Reactivation: Pharmacokinetic Study of the Asoxime-Cucurbit[7]uril Complex in Mice Using Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry

R. Andrýs, A. Klusoňová, M. Lísa, J. Kassa, JŽ. Karasová

. 2021 ; 18 (6) : 2416-2427. [pub] 20210521

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004226

Oxime-based molecules are used for the treatment of patients to reactivate acetylcholinesterase (AChE) function after organophosphate intoxication. However, their efficacy is limited by low penetration through the blood-brain barrier and fast elimination. In this work, the cucurbit[7]uril (CB[7]) carrier was used for the encapsulation of the clinical agent asoxime to enhance brain bioavailability and the treatment window. We present a pharmacokinetic study of asoxime and the asoxime-CB[7] complex in an in vivo mouse model. Ultrahigh-performance liquid chromatography with electrospray ionization-mass spectrometry detection was developed to determine asoxime and CB[7] in biological fluids and tissues after thorough optimization of chromatographic conditions. The dihydroxypropane-silica stationary phase using hydrophilic interaction liquid chromatography conditions provided the best chromatographic performance. The final method was validated and applied for the pharmacokinetic study of mouse plasma, urine, bile, liver, kidney, and brain samples at different times after administration of asoxime and the asoxime-CB[7] complex. The results showed a greater than 3-fold increase in the area under the curve (AUC) in the brain for asoxime administered as a complex with CB[7] relative to that for the administration of asoxime alone. The effectiveness of the treatment strategy was evaluated using a reactivation study and a functional observatory battery. Protection of brain AChE activity is crucial for saving human lives or reducing the consequences of poisoning. The asoxime administered as a complex increased the brain activity by approximately 30% compared to that with atropine alone. CB[7] coadministration improved the AChE activity by 11%, which agrees with the higher asoxime AUC assessed in the pharmacokinetic study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004226
003      
CZ-PrNML
005      
20220127145425.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.molpharmaceut.1c00257 $2 doi
035    __
$a (PubMed)34019427
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Andrýs, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic
245    10
$a Effect of Oxime Encapsulation on Acetylcholinesterase Reactivation: Pharmacokinetic Study of the Asoxime-Cucurbit[7]uril Complex in Mice Using Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry / $c R. Andrýs, A. Klusoňová, M. Lísa, J. Kassa, JŽ. Karasová
520    9_
$a Oxime-based molecules are used for the treatment of patients to reactivate acetylcholinesterase (AChE) function after organophosphate intoxication. However, their efficacy is limited by low penetration through the blood-brain barrier and fast elimination. In this work, the cucurbit[7]uril (CB[7]) carrier was used for the encapsulation of the clinical agent asoxime to enhance brain bioavailability and the treatment window. We present a pharmacokinetic study of asoxime and the asoxime-CB[7] complex in an in vivo mouse model. Ultrahigh-performance liquid chromatography with electrospray ionization-mass spectrometry detection was developed to determine asoxime and CB[7] in biological fluids and tissues after thorough optimization of chromatographic conditions. The dihydroxypropane-silica stationary phase using hydrophilic interaction liquid chromatography conditions provided the best chromatographic performance. The final method was validated and applied for the pharmacokinetic study of mouse plasma, urine, bile, liver, kidney, and brain samples at different times after administration of asoxime and the asoxime-CB[7] complex. The results showed a greater than 3-fold increase in the area under the curve (AUC) in the brain for asoxime administered as a complex with CB[7] relative to that for the administration of asoxime alone. The effectiveness of the treatment strategy was evaluated using a reactivation study and a functional observatory battery. Protection of brain AChE activity is crucial for saving human lives or reducing the consequences of poisoning. The asoxime administered as a complex increased the brain activity by approximately 30% compared to that with atropine alone. CB[7] coadministration improved the AChE activity by 11%, which agrees with the higher asoxime AUC assessed in the pharmacokinetic study.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a zvířata $7 D000818
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a hematoencefalická bariéra $x metabolismus $7 D001812
650    _2
$a přemostěné cyklické sloučeniny $x chemie $7 D001952
650    _2
$a cholinesterasové inhibitory $x aplikace a dávkování $x toxicita $7 D002800
650    _2
$a reaktivátory cholinesterázy $x aplikace a dávkování $x farmakokinetika $7 D002801
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a nosiče léků $x chemie $7 D004337
650    _2
$a enzymatické testy $7 D057075
650    _2
$a lidé $7 D006801
650    _2
$a hydrofobní a hydrofilní interakce $7 D057927
650    _2
$a imidazoly $x chemie $7 D007093
650    _2
$a hmotnostní spektrometrie $7 D013058
650    _2
$a myši $7 D051379
650    _2
$a otrava organofosfáty $x farmakoterapie $7 D062025
650    _2
$a oximy $x aplikace a dávkování $x farmakokinetika $7 D010091
650    _2
$a pyridinové sloučeniny $x aplikace a dávkování $x farmakokinetika $7 D011726
650    _2
$a sarin $x aplikace a dávkování $x toxicita $7 D012524
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Klusoňová, Aneta $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic
700    1_
$a Lísa, Miroslav $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic
700    1_
$a Kassa, Jiří $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences Hradec Králové, University of Defence, Tychonova 1, 160 00 Praha, Czech Republic
700    1_
$a Karasová, Jana Žd'árová $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences Hradec Králové, University of Defence, Tychonova 1, 160 00 Praha, Czech Republic
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 18, č. 6 (2021), s. 2416-2427
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34019427 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145422 $b ABA008
999    __
$a ok $b bmc $g 1751627 $s 1155375
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 18 $c 6 $d 2416-2427 $e 20210521 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...